F

Faes Farma SA
MAD:FAE

Watchlist Manager
Faes Farma SA
MAD:FAE
Watchlist
Price: 4.885 EUR -0.31% Market Closed
Market Cap: 1.5B EUR

Operating Margin
Faes Farma SA

17.9%
Current
22%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
17.9%
=
Operating Profit
101.9m
/
Revenue
568.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
ES
Faes Farma SA
MAD:FAE
1.5B EUR
18%
US
Eli Lilly and Co
NYSE:LLY
997.2B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
503.6B USD
27%
CH
Roche Holding AG
SIX:ROG
255.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
24%
CH
Novartis AG
SIX:NOVN
206.2B CHF
33%
US
Merck & Co Inc
NYSE:MRK
244.4B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
145.2B USD
29%
No Stocks Found

Faes Farma SA
Glance View

Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.

FAE Intrinsic Value
4.183 EUR
Overvaluation 14%
Intrinsic Value
Price
F
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
17.9%
=
Operating Profit
101.9m
/
Revenue
568.1m
What is the Operating Margin of Faes Farma SA?

Based on Faes Farma SA's most recent financial statements, the company has Operating Margin of 17.9%.

Back to Top